

Special Issue

Current Status of Monkeypox Vaccines

Message from the Guest Editor

Monkeypox disease has received some increased attention in the United States recently. This special issue will review the epidemiology, clinical manifestations in animals and humans, molecular biology of the virus, and vaccine considerations, including mechanisms of action, adverse effects, as well as the status of new and proposed vaccines. The current animal vectors and clinical trial data in humans will be reviewed. In this Special Issue, original research articles, reviews, as well as significant case reports are welcome. Research areas may include (but not limited to) the following:

- Monkeypox virus
- Monkeypox disease
- Animal vectors
- Molecular biology of the virus
- Vaccine mechanisms of action

We look forward to receiving your contributions. Prof. Dr. Lawrence D. Frenkel

Guest Editor

Prof. Dr. Lawrence Frenkel
St. Peter's University Hospital, New Brunswick, NJ, USA

Deadline for manuscript submissions

closed (30 November 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/167574

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).